

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q**

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File Number: 000-51222

Dexcom
DEXCOM, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

33-0857544

(I.R.S. Employer Identification No.)

6340 Sequence Drive, San Diego, CA

(Address of principal executive offices)

92121

(Zip Code)

(858) 200-0200

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common Stock, \$0.001 Par Value Per Share

Trading Symbol(s)

DXCM

Name of each exchange on which registered

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒

Non-accelerated filer ☐

Accelerated filer ☐

Smaller reporting company ☐Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 23, 2025, there were 390,016,272 shares of the registrant's common stock outstanding.

DexCom, Inc. Table of Contents

	Page
PART I. FINANCIAL INFORMATION	
ITEM 1. Financial Statements	
Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2025 and December 31, 2024	4
Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2025 and 2024	5
Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2025 and 2024	6
Condensed Consolidated Statements of Stockholders' Equity (unaudited) for the three and nine months ended September 30, 2025 and 2024	7
Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2025 and 2024	9
Notes to Condensed Consolidated Financial Statements (unaudited)	10
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	27
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	39
ITEM 4. Controls and Procedures	40
PART II. OTHER INFORMATION	
ITEM 1. Legal Proceedings	41
ITEM 1A. Risk Factors	42
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	44
ITEM 3. Defaults Upon Senior Securities	44
ITEM 4. Mine Safety Disclosures	44
ITEM 5. Other Information	45
ITEM 6. Exhibits	46
Signatures	48

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Except for historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Such statements include declarations regarding our operations, financial condition and prospects, and business strategies, and are based on management's intent, beliefs, expectations, and assumptions as of the date of this report. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control. Actual results could differ materially from those indicated or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission, or the SEC, on February 18, 2025, together with any updates identified under "Risk Factors" in our subsequently filed Quarterly Reports on Form 10-Q; and (iii) the other risks detailed from time-to-time in our other reports and registration statements filed with the SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

AVAILABLE INFORMATION

Our website address is located at www.dexcom.com and our investor relations website is located at investors.dexcom.com. We file electronically with the SEC our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.

We announce material information to the public about us, our products, and other matters through a variety of means, including filings with the SEC, press releases, public conference calls, presentations, webcasts, and our investor relations website, in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We also routinely post important information for investors on our website noted above, and we may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations portion of our website noted above. The information disclosed by the foregoing channels could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above and review the information disclosed through such channels.

Except as expressly set forth in this Quarterly Report on Form 10-Q, the contents of our website and our investor relations website are not incorporated by reference into, or otherwise to be regarded as part of, this Quarterly Report on Form 10-Q or any other report or document we file with the SEC, and any references to websites are intended to be inactive textual references only.

"Dexcom", "Dexcom Clarity", "Dexcom Follow", "Dexcom One", "Dexcom Share", "Stelo", and any related logos and design marks appearing in this Quarterly Report on Form 10-Q are either registered trademarks or trademarks of DexCom, Inc. in the United States and/or other countries. Other service marks, trademarks and trade names referred to in this Quarterly Report on Form 10-Q are the property of their respective owners.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

DexCom, Inc. Condensed Consolidated Balance Sheets (Unaudited)

(In millions, except share and par value data)

	September 30, 2025	December 31, 2024
Assets		
Current assets:		
Cash and cash equivalents	\$ 1,835.7	\$ 606.1
Short-term marketable securities	1,486.4	1,973.3
Accounts receivable, net	1,109.6	1,005.7
Inventory	604.1	542.6
Prepaid and other current assets	183.7	173.7
Total current assets	5,219.5	4,301.4
Property and equipment, net	1,471.3	1,339.9
Operating lease right-of-use assets	54.0	62.8
Goodwill	24.1	22.8
Intangibles, net	79.0	103.4
Deferred tax assets	375.6	481.2
Other assets	276.5	173.0
Total assets	\$ 7,500.0	\$ 6,484.5
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 1,932.4	\$ 1,585.1
Accrued payroll and related expenses	170.2	112.0
Current portion of long-term senior convertible notes	1,206.9	1,204.4
Short-term operating lease liabilities	23.6	22.5
Deferred revenue	2.9	8.0
Total current liabilities	3,336.0	2,932.0
Long-term senior convertible notes	1,239.9	1,237.0
Long-term operating lease liabilities	50.6	65.0
Other long-term liabilities	147.4	147.9
Total liabilities	4,773.9	4,381.9
Commitments and contingencies (Note 5)		
Stockholders' equity:		
Preferred stock, \$0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024	—	—
Common stock, \$0.001 par value, 800.0 million shares authorized; 410.6 million and 390.0 million shares issued and outstanding, respectively, at September 30, 2025; and 408.9 million and 390.7 million shares issued and outstanding, respectively, at December 31, 2024	0.4	0.4
Additional paid-in capital	2,246.5	2,093.8
Accumulated other comprehensive income (loss)	81.5	(8.0)
Retained earnings	2,166.6	1,597.6
Treasury stock, at cost; 20.6 million shares at September 30, 2025 and 18.2 million shares at December 31, 2024	(1,768.9)	(1,581.2)
Total stockholders' equity	2,726.1	2,102.6
Total liabilities and stockholders' equity	\$ 7,500.0	\$ 6,484.5

See accompanying notes

DexCom, Inc. Condensed Consolidated Statements of Operations (Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
<i>(In millions, except per share data)</i>				
Revenue	\$ 1,209.3	\$ 994.2	\$ 3,402.4	\$ 2,919.5
Cost of sales	477.9	400.4	1,393.2	1,137.1
Gross profit	731.4	593.8	2,009.2	1,782.4
Operating expenses:				
Research and development	157.5	135.4	450.9	412.9
Selling, general and administrative	331.4	306.4	969.5	958.4
Total operating expenses	488.9	441.8	1,420.4	1,371.3
Operating income	242.5	152.0	588.8	411.1
Other income, net	109.8	25.4	158.9	86.6
Income before income taxes	352.3	177.4	747.7	497.7
Income tax expense	68.5	42.8	178.7	73.2
Net income	\$ 283.8	\$ 134.6	\$ 569.0	\$ 424.5
Basic net income per share	\$ 0.73	\$ 0.34	\$ 1.45	\$ 1.08
Shares used to compute basic net income per share	391.1	394.2	391.4	394.6
Diluted net income per share	\$ 0.70	\$ 0.34	\$ 1.42	\$ 1.04
Shares used to compute diluted net income per share	407.4	410.2	407.7	414.7

See accompanying notes

DexCom, Inc.
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)

<i>(In millions)</i>	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Net income	\$ 283.8	\$ 134.6	\$ 569.0	\$ 424.5
Other comprehensive income (loss), net of tax:				
Translation adjustments and other	(3.6)	96.8	88.3	77.8
Unrealized gain on marketable debt securities	1.5	4.6	1.2	2.3
Total other comprehensive income (loss), net of tax	(2.1)	101.4	89.5	80.1
Comprehensive income	<u>\$ 281.7</u>	<u>\$ 236.0</u>	<u>\$ 658.5</u>	<u>\$ 504.6</u>

See accompanying notes

DexCom, Inc.

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)

	Three Months Ended September 30, 2025							
	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)		Retained Earnings	Treasury Stock	Total Stockholders' Equity
(In millions)	Shares	Amount		Translation Adjustments and Other	Net Unrealized Gain on Marketable Securities			
Balance at June 30, 2025	392.2	\$ 0.4	\$ 2,187.5	\$ 83.5	\$ 0.1	\$ 1,882.8	\$ (1,581.2)	\$ 2,573.1
Issuance of common stock for Employee Stock Purchase Plan	0.2	—	13.9	—	—	—	—	13.9
Purchases of treasury stock, including excise tax	(2.4)	—	—	—	—	—	(187.7)	(187.7)
Share-based compensation expense	—	—	45.1	—	—	—	—	45.1
Net income	—	—	—	—	—	283.8	—	283.8
Other comprehensive loss, net of tax	—	—	—	(3.6)	1.5	—	—	(2.1)
Balance at September 30, 2025	390.0	\$ 0.4	\$ 2,246.5	\$ 79.9	\$ 1.6	\$ 2,166.6	\$ (1,768.9)	\$ 2,726.1

	Three Months Ended September 30, 2024							
	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)		Retained Earnings	Treasury Stock	Total Stockholders' Equity
(In millions)	Shares	Amount		Translation Adjustments and Other	Net Unrealized Gain (Loss) on Marketable Securities			
Balance at June 30, 2024	400.7	\$ 0.4	\$ 1,992.3	\$ (36.0)	\$ (2.0)	\$ 1,311.3	\$ (831.7)	\$ 2,434.3
Issuance of common stock for Employee Stock Purchase Plan	0.3	—	14.8	—	—	—	—	14.8
Purchases of treasury stock, including excise tax	(10.4)	—	—	—	—	—	(749.5)	(749.5)
Share-based compensation expense	—	—	43.4	—	—	—	—	43.4
Net income	—	—	—	—	—	134.6	—	134.6
Other comprehensive income, net of tax	—	—	—	96.8	4.6	—	—	101.4
Balance at September 30, 2024	390.6	\$ 0.4	\$ 2,050.5	\$ 60.8	\$ 2.6	\$ 1,445.9	\$ (1,581.2)	\$ 1,979.0

See accompanying notes

DexCom, Inc.

Consolidated Statements of Stockholders' Equity

(Unaudited)

	Nine Months Ended September 30, 2025							
			Accumulated Other Comprehensive Income (Loss)					
					Net Unrealized Gain on Marketable Securities			
(In millions)	Common Stock Shares	Amount	Additional Paid-In Capital	Translation Adjustments and Other		Retained Earnings	Treasury Stock	Total Stockholders' Equity
Balance at December 31, 2024	390.7	\$ 0.4	\$ 2,093.8	\$ (8.4)	\$ 0.4	\$ 1,597.6	\$ (1,581.2)	\$ 2,102.6
Issuance of common stock under equity incentive plans	1.3	—	—	—	—	—	—	—
Issuance of common stock for Employee Stock Purchase Plan	0.4	—	28.1	—	—	—	—	28.1
Purchases of treasury stock, including excise tax	(2.4)	—	—	—	—	—	(187.7)	(187.7)
Share-based compensation expense	—	—	124.6	—	—	—	—	124.6
Net income	—	—	—	—	—	569.0	—	569.0
Other comprehensive income, net of tax	—	—	—	88.3	1.2	—	—	89.5
Balance at September 30, 2025	390.0	\$ 0.4	\$ 2,246.5	\$ 79.9	\$ 1.6	\$ 2,166.6	\$ (1,768.9)	\$ 2,726.1

	Nine Months Ended September 30, 2024							
	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)		Retained Earnings	Treasury Stock	Total Stockholders' Equity
(In millions)	Shares	Amount		Translation Adjustments and Other	Net Unrealized Gain on Marketable Securities			
Balance at December 31, 2023	385.4	\$ 0.4	\$ 3,514.6	\$ (17.0)	\$ 0.3	\$ 1,021.4	\$ (2,451.1)	\$ 2,068.6
Issuance of common stock under equity incentive plans	1.2	—	—	—	—	—	—	—
Issuance of common stock for Employee Stock Purchase Plan	0.4	—	28.2	—	—	—	—	28.2
Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs	1.5	—	(188.1)	—	—	—	188.1	—
Purchases of treasury stock, including excise tax	(10.4)	—	—	—	—	—	(749.5)	(749.5)
Exercise and settlement of warrants	12.5	—	(1,431.3)	—	—	—	1,431.3	—
Share-based compensation expense	—	—	127.1	—	—	—	—	127.1
Net income	—	—	—	—	—	424.5	—	424.5
Other comprehensive income, net of tax	—	—	—	77.8	2.3	—	—	80.1
Balance at September 30, 2024	390.6	\$ 0.4	\$ 2,050.5	\$ 60.8	\$ 2.6	\$ 1,445.9	\$ (1,581.2)	\$ 1,979.0

See accompanying notes

DexCom, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In millions)	Nine Months Ended September 30,	
	2025	2024
Operating activities		
Net income	\$ 569.0	\$ 424.5
Adjustments to reconcile net income to cash provided by operating activities:		
Depreciation and amortization	186.6	159.9
Share-based compensation	124.6	127.1
Non-cash interest expense	5.6	5.6
Deferred income taxes	103.3	(68.1)
Net (gains) losses on equity investments	(78.1)	1.4
Other non-cash income and expenses	(18.7)	(64.7)
Changes in operating assets and liabilities:		
Accounts receivable, net	(95.7)	(27.6)
Inventory	(45.9)	(20.3)
Prepaid and other assets	(7.9)	(13.8)
Operating lease right-of-use assets and liabilities, net	(4.5)	(3.0)
Accounts payable and accrued liabilities	357.1	231.7
Accrued payroll and related expenses	56.6	(64.3)
Deferred revenue and other liabilities	(5.3)	(0.3)
Net cash provided by operating activities	1,146.7	688.1
Investing activities		
Purchases of marketable securities	(1,246.6)	(2,083.5)
Proceeds from sale and maturity of marketable securities	1,755.1	2,419.2
Purchases of property and equipment	(261.6)	(234.2)
Purchases of non-marketable equity securities	(18.0)	(6.2)
Other investing activities	0.5	0.9
Net cash provided by investing activities	229.4	96.2
Financing activities		
Net proceeds from issuance of common stock	28.1	28.2
Purchases of treasury stock	(187.2)	(750.0)
Other financing activities	(5.1)	(11.4)
Net cash used in financing activities	(164.2)	(733.2)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	17.7	3.8
Increase in cash, cash equivalents and restricted cash	1,229.6	54.9
Cash, cash equivalents and restricted cash, beginning of period	607.3	567.5
Cash, cash equivalents and restricted cash, end of period	\$ 1,836.9	\$ 622.4
Reconciliation of cash, cash equivalents and restricted cash, end of period:		
Cash and cash equivalents	\$ 1,835.7	\$ 621.2
Restricted cash	1.2	1.2
Total cash, cash equivalents and restricted cash	\$ 1,836.9	\$ 622.4
Supplemental disclosure of non-cash investing and financing transactions:		
Acquisition of property and equipment included in accounts payable and accrued liabilities	\$ 46.4	\$ 77.6
Right-of-use assets obtained in exchange for operating lease liabilities	\$ 2.7	\$ 8.2
Right-of-use assets obtained in exchange for finance lease liabilities	\$ 1.4	\$ 11.8

See accompanying notes

DexCom, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. Organization and Significant Accounting Policies

Organization and Business

We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries.

Basis of Presentation and Principles of Consolidation

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.

Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2025.

These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto for the fiscal year ended December 31, 2024 included in the Annual Report on Form 10-K that we filed with the SEC on February 18, 2025.

These condensed consolidated financial statements include the accounts of DexCom, Inc. and our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

We have reclassified certain prior period amounts to conform to the current period presentation.

We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive income (loss) in the equity section of our condensed consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income, net in our condensed consolidated statements of operations.

Significant Accounting Policies

There were no material changes during the nine months ended September 30, 2025 to our significant accounting policies as described in Note 1 “*Organization and Significant Accounting Policies*” to the financial statements in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include pharmacy rebates, excess and obsolete inventories, loss contingencies, and the amount of our worldwide tax provision. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.

Concentration of Credit Risk

Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position. We monitor the creditworthiness of our customers based on historical trends, the financial condition of our customers, and external market factors.

Contract Balances

Contract balances represent amounts presented in our condensed consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from 30 to 90 days.

Accounts receivable as of September 30, 2025 and December 31, 2024 included unbilled accounts receivable of \$16.6 million and \$15.2 million, respectively. We expect to invoice and collect all unbilled accounts receivable within twelve months.

We record deferred revenue when cash payments have been received prior to satisfaction of the related performance obligation. Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months were \$8.5 million as of September 30, 2025 and \$9.5 million as of December 31, 2024. These balances are included in other long-term liabilities in our condensed consolidated balance sheets.

Net Income Per Share

Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.

Potentially dilutive common shares consist of shares issuable from restricted stock units, or RSUs, performance stock units, or PSUs, warrants, our senior convertible notes, and collaborative sales-based milestones. Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method.

The following table sets forth the computation of basic and diluted net income per share for the periods shown:

(In millions, except per share data)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Net income	\$ 283.8	\$ 134.6	\$ 569.0	\$ 424.5
Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes	2.8	2.9	8.6	8.7
Net income - diluted	\$ 286.6	\$ 137.5	\$ 577.6	\$ 433.2
Net income per common share				
Basic	\$ 0.73	\$ 0.34	\$ 1.45	\$ 1.08
Diluted	\$ 0.70	\$ 0.34	\$ 1.42	\$ 1.04
Basic weighted average shares outstanding	391.1	394.2	391.4	394.6
Dilutive potential securities:				
Collaborative sales-based milestones	—	—	—	0.3
RSUs and PSUs	0.6	0.3	0.6	0.7
Senior convertible notes	15.7	15.7	15.7	15.7
Warrants	—	—	—	3.4
Diluted weighted average shares outstanding	407.4	410.2	407.7	414.7

Outstanding anti-dilutive securities not included in the calculations of diluted net income per share attributable to common stockholders were as follows:

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
RSUs and PSUs	0.9	2.2	1.1	1.3

Recent Accounting Guidance

Recently Issued Accounting Pronouncements Not Yet Adopted

In December 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-09, *Improvements to Income Tax Disclosures*. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity's exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024. We will adopt the standard on December 31, 2025.

In November 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses*. The ASU requires disaggregated disclosure of certain costs and expenses in the notes to the financial statements. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The ASU may be applied on either a prospective or a retrospective basis. We are currently evaluating the impact of this standard on our disclosures.

In November 2024, the FASB issued ASU 2024-04, *Debt-Debt with Conversion and Other Options*. The ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The ASU is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual reporting periods, with early adoption permitted. The ASU may be applied on either a prospective or a retrospective basis. We are currently evaluating the impact of this standard on our condensed consolidated financial statements.

2. Fair Value Measurements

Assets and Liabilities Measured at Fair Value on a Recurring Basis

We estimate the fair values of our Level 1 financial instruments, which are in active markets, using unadjusted quoted market prices for identical instruments.

We obtain the fair values of our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset.

We estimate the fair values of our Level 3 financial instruments based on unobservable inputs and other estimation techniques due to the absence of quoted market prices and inherent lack of liquidity.

The following table summarizes financial assets that we measured at fair value on a recurring basis as of September 30, 2025, classified in accordance with the fair value hierarchy:

(In millions)	Fair Value Measurements Using			
	Level 1	Level 2	Level 3	Total
Cash equivalents	\$ 1,005.3	\$ 367.9	\$ —	\$ 1,373.2
Debt securities, available-for-sale:				
U.S. government agencies ⁽¹⁾	—	648.6	—	648.6
Commercial paper	—	172.2	—	172.2
Corporate debt	—	665.6	—	665.6
Total debt securities, available-for-sale	—	1,486.4	—	1,486.4
Other long-term assets:				
Convertible notes receivable	—	—	10.5	10.5
Other assets ⁽²⁾	20.5	—	—	20.5
Total assets measured at fair value on a recurring basis	\$ 1,025.8	\$ 1,854.3	\$ 10.5	\$ 2,890.6

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

⁽²⁾ Includes assets which are primarily held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.

The following table summarizes financial assets that we measured at fair value on a recurring basis as of December 31, 2024, classified in accordance with the fair value hierarchy:

(In millions)	Fair Value Measurements Using			
	Level 1	Level 2	Level 3	Total
Cash equivalents	\$ 134.2	\$ —	\$ —	\$ 134.2
Debt securities, available-for-sale:				
U.S. government agencies ⁽¹⁾	—	1,150.1	—	1,150.1
Commercial paper	—	312.1	—	312.1
Corporate debt	—	511.1	—	511.1
Total debt securities, available-for-sale	—	1,973.3	—	1,973.3
Other long-term assets:				
Convertible notes receivable	—	—	10.5	10.5
Other assets ⁽²⁾	20.6	—	—	20.6
Total assets measured at fair value on a recurring basis	\$ 154.8	\$ 1,973.3	\$ 10.5	\$ 2,138.6

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

⁽²⁾ Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.

There were no transfers into or out of Level 3 securities during the three and nine months ended September 30, 2025 and September 30, 2024.

Fair Value of Senior Convertible Notes

The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:

(In millions)	Fair Value Measurements Using Level 1	
	September 30, 2025	December 31, 2024
Senior Convertible Notes due 2025	\$ 1,199.6	\$ 1,163.7
Senior Convertible Notes due 2028	1,140.4	1,122.3
Total fair value of outstanding senior convertible notes	\$ 2,340.0	\$ 2,286.0

See Note 4 “Debt—Senior Convertible Notes” to the condensed consolidated financial statements for more information regarding the carrying values of our senior convertible notes.

Foreign Currency and Derivative Financial Instruments

As we conduct business globally in many currencies, we are exposed to foreign exchange rate changes. To limit this exposure, we enter into foreign currency forward contracts to hedge monetary assets and liabilities, including intercompany loans, denominated in non-functional currencies. Our foreign currency forward contracts are not designated as hedging instruments. Therefore, changes in the fair values of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The duration of these contracts are generally one to three months. The derivative gains and losses are included in other income, net in our condensed consolidated statements of operations.

As of September 30, 2025 and December 31, 2024, the notional amounts of outstanding foreign currency forward contracts were \$214.0 million and \$66.0 million, respectively. The resulting impact on our condensed consolidated financial statements from currency hedging activities was not significant for the three and nine months ended September 30, 2025 and September 30, 2024.

We monitor the costs and the impact of foreign currency risks upon our financial results as part of our risk management program. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management. We do not require and are not required to pledge collateral for these financial instruments and we do not carry any master netting arrangements to mitigate the credit risk.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

In accordance with authoritative guidance, we measure certain non-financial assets and liabilities at fair value on a non-recurring basis. These measurements are usually performed using the discounted cash flow method or cost method and Level 3 inputs. These include items such as non-financial assets and liabilities initially measured at fair value in a business combination and non-financial long-lived assets measured at fair value for an impairment assessment. In general, non-financial assets, including goodwill, intangible assets, and property and equipment, are measured at fair value when there are indicators of impairment and are recorded at fair value only when an impairment is recognized.

Our non-marketable equity investments without readily determinable fair values are accounted for under the measurement alternative. As such, we measure these investments at cost less impairment, adjusted for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are privately held and limited information is available. We include the carrying values of these investments in other assets in our condensed consolidated balance sheets. Adjustments to the carrying values of these investments as a result of observable price changes and impairments are recorded in other income, net in our condensed consolidated statements of operations.

The carrying values of the non-marketable equity investments were \$216.9 million as of September 30, 2025 and \$119.3 million as of December 31, 2024. During the three and nine months ended September 30, 2025, we recorded upward adjustments of \$82.5 million for observable price changes.

There were no significant impairment losses on assets and liabilities measured at fair value on a non-recurring basis during the three and nine months ended September 30, 2025 and September 30, 2024.

3. Balance Sheet Details and Other Financial Information

Short-Term Marketable Securities

Our available-for-sale debt securities were as follows as of the dates indicated:

(In millions)	September 30, 2025			
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Market Value
Debt securities, available-for-sale:				
U.S. government agencies ⁽¹⁾	\$ 648.0	\$ 0.7	\$ (0.1)	\$ 648.6
Commercial paper	172.3	—	(0.1)	172.2
Corporate debt	664.5	1.1	—	665.6
Total debt securities, available-for-sale	\$ 1,484.8	\$ 1.8	\$ (0.2)	\$ 1,486.4

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

(In millions)	December 31, 2024			
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Market Value
Debt securities, available-for-sale:				
U.S. government agencies ⁽¹⁾	\$ 1,149.4	\$ 1.3	\$ (0.6)	\$ 1,150.1
Commercial paper	312.2	—	(0.1)	312.1
Corporate debt	511.1	0.4	(0.4)	511.1
Total debt securities, available-for-sale	\$ 1,972.7	\$ 1.7	\$ (1.1)	\$ 1,973.3

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

As of September 30, 2025, the estimated market values of our short-term debt securities with contractual maturities up to 12 months and up to 18 months were \$1.41 billion and \$76.3 million, respectively. As of December 31, 2024, the estimated market values of our short-term debt securities with contractual maturities up to 12 months and up to 18 months were \$1.73 billion and \$247.7 million, respectively. Gross realized gains and losses on sales of our short-term debt securities for the three and nine months ended September 30, 2025 and September 30, 2024 were not significant.

We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities at September 30, 2025 were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

Inventory

(In millions)	September 30, 2025	December 31, 2024
Raw materials	\$ 266.0	\$ 327.1
Work-in-process	78.6	28.1
Finished goods	259.5	187.4
Total inventory	\$ 604.1	\$ 542.6

We recorded excess and obsolete inventory charges of \$16.0 million and \$23.3 million, during the three months ended September 30, 2025 and 2024, respectively, and \$53.0 million and \$32.7 million during the nine months ended September 30, 2025 and 2024, respectively. These charges are recorded in cost of sales and reflect reserves established through our ongoing evaluation of quality control data, forecasted demand, and the continued improvement and innovation of our products.

Prepaid and Other Current Assets

(In millions)	September 30, 2025	December 31, 2024
Prepaid expenses	\$ 68.9	\$ 87.5
Deferred compensation plan assets	20.5	18.6
Income tax receivables	48.6	27.9
Indirect tax receivables	11.2	10.6
Other current assets	34.5	29.1
Total prepaid and other current assets	\$ 183.7	\$ 173.7

Property and Equipment

(In millions)	September 30, 2025	December 31, 2024
Building	\$ 310.5	\$ 291.0
Computer software and hardware	85.9	76.6
Furniture and fixtures	40.3	40.2
Land and land improvements	56.5	53.1
Leasehold improvements	296.5	293.8
Machinery and equipment	999.4	908.9
Construction in progress	491.7	354.6
Total cost	2,280.8	2,018.2
Less: accumulated depreciation and amortization	(809.5)	(678.3)
Total property and equipment, net	\$ 1,471.3	\$ 1,339.9

Other Assets

(In millions)	September 30, 2025	December 31, 2024
Non-marketable equity securities	\$ 216.9	\$ 119.3
Long-term deposits	16.8	13.8
Other assets	42.8	39.9
Total other assets	\$ 276.5	\$ 173.0

Accounts Payable and Accrued Liabilities

(In millions)	September 30, 2025	December 31, 2024
Accounts payable trade	\$ 451.5	\$ 345.3
Accrued rebates	1,373.3	1,135.9
Accrued tax, audit, and legal fees	21.0	38.4
Accrued warranty	17.3	5.9
Deferred compensation plan liabilities	20.5	18.6
Income tax payable	6.8	3.9
Other accrued liabilities	42.0	37.1
Total accounts payable and accrued liabilities	\$ 1,932.4	\$ 1,585.1

Accrued Payroll and Related Expenses

(In millions)	September 30, 2025	December 31, 2024
Accrued wages, bonus and taxes	\$ 141.9	\$ 74.5
Other accrued employee benefits	28.3	37.5
Total accrued payroll and related expenses	<u>\$ 170.2</u>	<u>\$ 112.0</u>

Other Long-Term Liabilities

(In millions)	September 30, 2025	December 31, 2024
Asset retirement obligation	\$ 17.6	\$ 17.0
Finance lease obligations	54.6	58.5
Other tax liabilities	49.5	44.8
Other liabilities	25.7	27.6
Total other long-term liabilities	<u>\$ 147.4</u>	<u>\$ 147.9</u>

Other Income, Net

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Interest and dividend income	\$ 32.7	\$ 32.0	\$ 89.2	\$ 104.5
Interest expense	(4.7)	(4.7)	(14.1)	(14.1)
Net gains (losses) on equity investments	82.7	0.4	78.1	(1.4)
Other income (expense), net	(0.9)	(2.3)	5.7	(2.4)
Total other income, net	<u>\$ 109.8</u>	<u>\$ 25.4</u>	<u>\$ 158.9</u>	<u>\$ 86.6</u>

4. Debt

Senior Convertible Notes

The carrying amounts of our senior convertible notes were as follows as of the dates indicated:

(In millions)	September 30, 2025	December 31, 2024
Principal amount:		
Senior Convertible Notes due 2025	\$ 1,207.5	\$ 1,207.5
Senior Convertible Notes due 2028	1,250.0	1,250.0
Total principal amount	2,457.5	2,457.5
Unamortized debt issuance costs	(10.7)	(16.1)
Carrying amount of senior convertible notes	<u>\$ 2,446.8</u>	<u>\$ 2,441.4</u>

As of September 30, 2025 and December 31, 2024, the if-converted value of our unsecured senior convertible notes due 2025, or the 2025 Notes, and our unsecured senior convertible notes due 2028, or the 2028 Notes, did not exceed their outstanding principal amount.

The following table summarizes the components of interest expense and the effective interest rates for our senior convertible notes for the periods shown:

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Cash interest expense:				
Contractual coupon interest ⁽¹⁾	\$ 1.9	\$ 1.9	\$ 5.8	\$ 5.8
Non-cash interest expense:				
Amortization of debt issuance costs	1.8	1.8	5.4	5.4
Total interest expense recognized on senior notes	<u>\$ 3.7</u>	<u>\$ 3.7</u>	<u>\$ 11.2</u>	<u>\$ 11.2</u>
Effective interest rate:				
Senior Convertible Notes due 2025	0.5 %	0.5 %	0.5 %	0.5 %
Senior Convertible Notes due 2028	0.7 %	0.7 %	0.7 %	0.7 %

⁽¹⁾ Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.

Convertible Debt Summary

The following table summarizes key details of the 2025 Notes and 2028 Notes:

Senior Convertible Notes	Offering Completion Date	Maturity Date	Stated Interest Rate	Aggregate Principal Amount Issued	Net Proceeds ⁽¹⁾	Initial Conversion Rate ⁽²⁾ (per \$1,000 principal amount)	Conversion Price (per share)	Settlement Methods ⁽³⁾
2025 Notes	May 2020	November 15, 2025	0.25%	\$1.21 billion	\$1.19 billion	6.6620 shares	\$150.11	Cash and/or shares
2028 Notes	May 2023	May 15, 2028	0.375%	\$1.25 billion	\$1.23 billion	6.1571 shares	\$162.41	Cash and/or shares

⁽¹⁾ Net proceeds are calculated by deducting the initial purchasers' discounts and estimated costs directly related to the offering from the aggregate principal amount of the applicable series of notes.

⁽²⁾ Subject to adjustments as defined in the applicable indentures.

⁽³⁾ Pursuant to the Indenture of the 2025 Notes, on August 15, 2025, we elected to satisfy conversion obligations on or after August 15, 2025 through the combination of cash and/or shares of our common stock. The 2028 Notes may be settled upon conversion in cash, stock, or a combination thereof, solely at our discretion.

We use the if-converted method for assumed conversion of our senior convertible notes to compute the weighted average shares of common stock outstanding for diluted earnings per share.

No principal payments are due on any of our senior convertible notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indentures relating to our senior convertible notes include customary terms and covenants, including certain events of default after which the senior convertible notes may be due and payable immediately.

2028 Capped Call Transactions

In May 2023, in connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions, or the 2028 Capped Calls, with certain financial institutions. The 2028 Capped Calls cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2028 Notes, the number of shares of our common stock initially underlying the 2028 Notes. The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, as the case may be, with such reduction and/or offset subject to a cap. The 2028 Capped Calls have an initial cap price of \$212.62 per share, subject to adjustments, which represents a premium of 80% over the closing price of our common stock of \$118.12 per share on the Nasdaq Global Select Market on May 2, 2023. The cost to purchase the 2028 Capped Calls of \$101.3 million was recorded as a reduction to additional paid-in capital in our condensed consolidated balance sheets as the 2028 Capped Calls met the criteria for classification in stockholders' equity.

Conversion Activity for Senior Convertible Notes

There was no conversion activity for the 2025 Notes or 2028 Notes for the nine months ended September 30, 2025.

Conversion Rights for Senior Convertible Notes

Holders of our outstanding senior convertible notes have the right to require us to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the applicable indenture relating to the notes). We are also required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by Dexcom of a notice of redemption.

The following table outlines the conversion options related for each of our senior convertible notes:

Summary of Conversions Rights at the Option of the Holders for the 2025 Notes and 2028 Notes, which we refer to collectively as the Notes

Conversion Rights at the Option of the Holders	Holders of the Notes have the ability to convert all or a portion of their notes in multiples of \$1,000 principal amount, at their option prior to 5:00 p.m., New York City time, on the business day immediately preceding August 15, 2025 and February 15, 2028 for the 2025 Notes and 2028 Notes, respectively, only under the following circumstances:
Circumstance 1⁽¹⁾	During any calendar quarter commencing after the applicable period (and only during such calendar quarter), if the last reported sale price of Dexcom's common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price for the Notes on each applicable trading day
Circumstance 2	During the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Notes for each trading day of that five consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom's common stock and the applicable conversion rate of the Notes on each such trading day
Circumstance 3	If we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date (only with respect to the notes called or deemed called for redemption)
Circumstance 4	Upon the occurrence of specified corporate events
Circumstance 5⁽²⁾	Holders of the Notes may convert all or a portion of their Notes regardless of the foregoing circumstances prior to the close of business on the business day immediately preceding the maturity date for the 2025 Notes and prior to the close of business on the second scheduled trading day immediately preceding the maturity date for the 2028 Notes

⁽¹⁾ Circumstance 1 is available after the calendar quarter ended September 30, 2020 and September 30, 2023 for the 2025 Notes and 2028 Notes, respectively.

⁽²⁾ Circumstance 5 is available on or after August 15, 2025 and February 15, 2028 for the 2025 Notes and 2028 Notes, respectively.

Summary of Conversion Right at the Option of the Company for the 2025 Notes and 2028 Notes

Conversion Right at Our Option⁽¹⁾	Dexcom may redeem for cash all or part of the Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date
---	---

⁽¹⁾ Dexcom does not have the right to redeem the Notes prior to May 20, 2023 and May 20, 2026 for the 2025 Notes and 2028 Notes, respectively. Dexcom has the right to redeem the notes on or after May 20, 2023 and prior to August 15, 2025 for the 2025 Notes, and on or after May 20, 2026 and prior to February 15, 2028 for the 2028 Notes.

Amended Credit Agreement

Terms of the Amended Credit Agreement

In June 2023, we entered into the First Amendment to the Second Amended and Restated Credit Agreement, as amended, or the Amended Credit Agreement, which we had previously entered into in October 2021. The Amended Credit Agreement is a five-year revolving credit facility, or the Credit Facility, that provides for an available principal amount of \$200.0 million which can be increased up to \$500.0 million at our option subject to customary conditions and approval of our lenders. The Amended Credit Agreement will mature on October 13, 2026. Borrowings under the Amended Credit Agreement are available for general corporate purposes, including working capital and capital expenditures.

Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:

<i>(In millions)</i>	September 30, 2025
Available principal amount	\$ 200.0
Letters of credit sub-facility	25.0
Outstanding borrowings	—
Outstanding letters of credit	7.7
Total available balance	\$ 192.3

Revolving loans under the Amended Credit Agreement bear interest at our choice of one of three base rates plus a range of applicable rates that are based on our leverage ratio. The minimum and maximum range of applicable rates per annum with respect to any ABR Loan, Term Benchmark Revolving Loan, or RFR Revolving Loan, each as defined in the Amended Credit Agreement under the captions “ABR Spread”, “Term Benchmark”, and “RFR Spread”, or “Unused Commitment Fee Rate”, respectively, are outlined in the following table:

Range	ABR Spread	Term Benchmark/RFR Spread	Unused Commitment Fee Rate
Minimum	0.375%	1.375%	0.175%
Maximum	1.000%	2.000%	0.250%

Our obligations under the Amended Credit Agreement are guaranteed by our existing and future wholly-owned domestic subsidiaries, and are secured by a first-priority security interest in substantially all of the assets of Dexcom and the guarantors, including all or a portion of the equity interests of our domestic subsidiaries and first-tier foreign subsidiaries but excluding real property and intellectual property (which is subject to a negative pledge). The Amended Credit Agreement contains covenants that limit certain indebtedness, liens, investments, transactions with affiliates, dividends and other restricted payments, subordinated indebtedness and amendments to subordinated indebtedness documents, and sale and leaseback transactions of Dexcom or any of its domestic subsidiaries. The Amended Credit Agreement also requires us to maintain a maximum leverage ratio and a minimum fixed charge coverage ratio. We were in compliance with these covenants as of September 30, 2025.

As of September 30, 2025, we have other guarantee facilities related to certain international operations that are partially collateralized, which are included in non-current “Other assets” on our condensed consolidated balance sheets. These facilities are not significant to the condensed consolidated financial statements.

5. Contingencies

Litigation

We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.

Due to uncertainty surrounding the securities class action litigation and the derivative actions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to defend against these claims vigorously in all of these actions.

We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.

6. Income Taxes

We estimate our annual effective tax rate to be 22.5% for the full year 2025, which differs from the U.S. federal statutory rate due to state and foreign income taxes, federal taxation of international operations, and nondeductible executive compensation, partially offset by federal tax credits generated. Our actual effective tax rate of 23.9% for the nine months ended September 30, 2025 compared to the estimated annual effective tax rate of 22.5%, was higher primarily due to shortfalls recognized for employee share-based compensation, net of disallowed executive compensation, partially offset by the tax benefit related to the commencement of our Malaysia tax holiday.

On July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law in the U.S., and includes a broad range of tax reform provisions. We have considered the impact of the OBBBA on the Company's annual effective tax rate, and determined these changes did not have a significant impact to the annual effective tax rate. We expect the primary impact of this legislation to be a reduction in our U.S. income tax liability related to the ability to currently deduct U.S.-based research expenses against U.S. income.

During the third quarter of 2025, the Malaysia Investment Development Authority, or MIDA, certified our achievement of the milestones and conditions related to our Malaysia income tax holiday. We have recorded a tax benefit related to the retroactive application of the tax holiday back to January 1, 2024.

The Organization for Economic Co-operation and Development's, or OECD, Pillar Two Initiative introduced a 15% global minimum tax for certain multinational groups exceeding minimum annual global revenue thresholds. Some countries in which the Company operates have enacted legislation adopting the minimum tax effective January 1, 2024. As of September 30, 2025, we are subject to Pillar Two minimum tax in Malaysia due to the commencement of our tax holiday. Otherwise, we do not expect the implementation of the OECD Pillar Two global minimum tax rules, including the transitional safe harbor provisions, to have a material impact on our consolidated financial statements. We continue to monitor legislative developments and interpretive guidance across relevant jurisdictions and will assess the potential implications of these rules and potential changes in our financial forecast and include any appropriate minimum tax in our annual effective tax rate for the calendar year.

7. Stockholders' Equity

Share-Based Compensation

Our share-based compensation expense is associated with RSUs, PSUs, and our Employee Stock Purchase Plan, or ESPP. The following table summarizes our share-based compensation expense included in our condensed consolidated statements of operations for the periods shown:

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Cost of sales	\$ 1.0	\$ 3.6	\$ 8.2	\$ 11.4
Research and development	12.2	13.1	38.5	38.5
Selling, general and administrative	31.9	26.7	77.9	77.2
Total share-based compensation expense	\$ 45.1	\$ 43.4	\$ 124.6	\$ 127.1

As of September 30, 2025, unrecognized estimated compensation costs related to RSUs and PSUs totaled \$243.2 million and are expected to be recognized over a weighted-average period of approximately 1.9 years.

Share Repurchase Program and Treasury Shares

In April 2025, our Board of Directors authorized and approved a share repurchase program of up to \$750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2026, or the 2025 Share Repurchase Program. Repurchases of our common stock under the 2025 Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, at our discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at our discretion. The 2025 Share Repurchase Program does not obligate us to repurchase any dollar amount or number of shares of our common stock, and the program may be extended, modified, suspended, or discontinued at any time.

In the third quarter of 2025, we repurchased 2.4 million shares of our common stock for \$187.2 million under the 2025 Share Repurchase Program.

Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. We have not yet determined the ultimate disposition of repurchased shares and consequently we continue to hold them as treasury shares rather than retiring them. Authorization of future stock repurchase programs is subject to the final determination of our Board of Directors.

8. Business Segment and Geographic Information

We manage our business on a global consolidated basis within one operating and one reportable segment, which is consistent with how our chief operating decision maker (CODM) reviews our business, makes investment and resource allocation decisions, and assesses operating performance. The majority of our revenue is generated in the United States. Our reportable segment derives revenues from the sale of disposable sensors and our Reusable Hardware. Effective September 14, 2025, our President and Chief Operating Officer, assumed the role of interim principal executive officer and CODM while our CEO was on medical leave. This did not result in a change to our segments.

The measures of segment profit or loss that are most consistent with U.S. GAAP used by the CODM to assess performance and allocate resources are operating income and net income. Our CODM also reviews total assets, as reported on our condensed consolidated balance sheets, and purchases of property and equipment, as reported on our condensed consolidated statements of cash flows.

Our CODM uses operating income and net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the Company, acquire companies, or invest in other companies. Operating income is the primary segment performance measure used to monitor budget versus actual results.

The following table sets forth our segment information for revenue, measures of segment profit or loss, and significant expenses:

(In millions)	Three Months Ended September 30, 2025		Nine Months Ended September 30, 2025	
	2025	2024	2025	2024
Revenue	\$ 1,209.3	\$ 994.2	\$ 3,402.4	\$ 2,919.5
Less:				
Cost of sales ⁽¹⁾	477.9	400.4	1,393.2	1,137.1
Payroll related expenses	233.2	179.9	675.4	569.2
Stock-based compensation expense	44.1	39.8	116.4	115.7
Marketing expense	75.7	65.7	224.9	213.6
Travel related expenses	15.2	14.5	49.1	51.6
Supply expenses and clinical trials	17.7	18.2	45.8	50.9
Consulting & professional fees	33.1	59.9	100.9	175.1
Equipment, office & facility expenses	22.8	20.3	66.8	63.4
IT software and data	36.8	33.2	107.9	96.6
Depreciation and amortization	9.6	9.5	28.1	30.6
Other segment items ⁽²⁾	0.7	0.8	5.1	4.6
Operating income	242.5	152.0	588.8	411.1
Other income, net	109.8	25.4	158.9	86.6
Income tax expense	68.5	42.8	178.7	73.2
Net income	\$ 283.8	\$ 134.6	\$ 569.0	\$ 424.5

⁽¹⁾ Includes amounts stated in other significant expense captions.

⁽²⁾ Other segment items are primarily composed of impairment of assets and bad debt expense.

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Other segment disclosures				
Depreciation and amortization ⁽¹⁾	\$ 63.6	\$ 55.3	\$ 186.6	\$ 159.9
Expenditures for long-lived assets	\$ 80.5	\$ 111.2	\$ 261.6	\$ 234.2
Significant noncash items other than depreciation and amortization expense:				
Deferred income tax expense (benefit)	\$ 118.0	\$ (11.6)	\$ 103.3	\$ (68.1)
Net (gains) losses on equity investments	\$ (82.7)	\$ (0.4)	\$ (78.1)	\$ 1.4

⁽¹⁾ Includes depreciation and amortization recorded in both cost of sales and operating expenses.

See Note 3 “*Balance Sheet Details and Other Financial Information—Other Income, Net*” to the condensed consolidated financial statements for information about our interest income and interest expense.

See Note 7 “*Stockholders’ Equity—Share-Based Compensation*” to the condensed consolidated financial statements for information about our share-based compensation expense.

Disaggregation of Revenue

We disaggregate revenue by major sales channel and by geographic region. We have determined that disaggregating revenue into these categories achieves the ASC Topic 606 disclosure objectives of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Revenue by Customer Sales Channel

We sell our CGM systems through a direct sales organization and through distribution arrangements that allow distributors to sell our products. The following table sets forth revenue by major sales channel for the periods shown:

(In millions)	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024	
	Amount	% of Total	Amount	% of Total
Distributor	\$ 1,026.0	85 %	\$ 843.3	85 %
Direct	183.3	15 %	150.9	15 %
Total revenue	\$ 1,209.3	100 %	\$ 994.2	100 %

(In millions)	Nine Months Ended September 30, 2025		Nine Months Ended September 30, 2024	
	Amount	% of Total	Amount	% of Total
Distributor	\$ 2,883.8	85 %	\$ 2,482.2	85 %
Direct	518.6	15 %	437.3	15 %
Total revenue	\$ 3,402.4	100 %	\$ 2,919.5	100 %

Revenue by Geographic Region

During the three and nine months ended September 30, 2025 and September 30, 2024, no individual country outside the United States generated revenue that represented more than 10% of our total revenue. The following table sets forth revenue by our two primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:

(In millions)	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024	
	Amount	% of Total	Amount	% of Total
United States	\$ 851.9	70 %	\$ 701.9	71 %
International	357.4	30 %	292.3	29 %
Total revenue	\$ 1,209.3	100 %	\$ 994.2	100 %

(In millions)	Nine Months Ended September 30, 2025		Nine Months Ended September 30, 2024	
	Amount	% of Total	Amount	% of Total
United States	\$ 2,443.4	72 %	\$ 2,087.0	71 %
International	959.0	28 %	832.5	29 %
Total revenue	\$ 3,402.4	100 %	\$ 2,919.5	100 %

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q, including the following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that are not purely historical regarding Dexcom's or its management's intentions, beliefs, expectations and strategies for the future. These forward-looking statements fall within the meaning of the federal securities laws that relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "expect," "plan," "anticipate," "believe," "estimate," "intend," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that could cause actual results to differ materially are more fully described under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on February 18, 2025, together with any updates identified under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q, elsewhere in this Quarterly Report on Form 10-Q, and in our other reports filed with the SEC. We assume no obligation to update any of the forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these forward-looking statements to actual results. You should read the following discussion and analysis together with our condensed consolidated financial statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Overview

Who We Are

We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.

We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G6 integrated Continuous Glucose Monitoring System, or G6, in 2018, and we launched the Dexcom G7, or G7, in 2023. In August 2024, we launched Stelo, our biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S. In April 2025, we received FDA clearance for the Dexcom G7 15 Day CGM System for people over the age of 18 with diabetes in the United States.

Unless the context requires otherwise, the terms "we," "us," "our," the "company," or "Dexcom" refer to DexCom, Inc. and its subsidiaries.

Global Presence

We have built a direct sales organization in North America and certain international markets to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. To complement our direct sales efforts, we have entered into distribution arrangements in North America and several international markets that allow distributors to sell our products.

Future Developments

Product Development: We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.

Partnerships: We continue to support partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. With the introduction of Stelo, we are also pursuing and supporting development partnerships with consumer technology product companies that seek to provide metabolic health insights to their customers.

New Opportunities: We are also exploring how to extend our offerings to other opportunities, including for people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the estimates, assumptions and judgments involved in the accounting policies described in “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. There were no material changes to our critical accounting estimates during the nine months ended September 30, 2025.

Overview of Financial Results

The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow.

Key Highlights for the Three Months Ended September 30, 2025 include the following:

Revenue	Gross Profit	Operating Income	Net Income	Operating Cash Flow
\$1.21 billion	\$731.4 million	\$242.5 million	\$283.8 million	\$659.9 million
up 22% from the same period in 2024	up 23% from the same period in 2024	up 60% from the same period in 2024	up 111% from the same period in 2024	up 231% from the same period in 2024

We ended the third quarter of 2025 with cash, cash equivalents and short-term marketable securities totaling \$3.32 billion.

Results of Operations

Financial Overview

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

(In millions, except per share amounts)	Three Months Ended September 30,				2025 - 2024	
	2025	% of Revenue ⁽¹⁾	2024	% of Revenue ⁽¹⁾	\$ Change	% Change
Revenue	\$ 1,209.3	100 %	\$ 994.2	100 %	\$ 215.1	22 %
Cost of sales	477.9	40 %	400.4	40 %	77.5	19 %
Gross profit	731.4	60.5 %	593.8	59.7 %	137.6	23 %
Operating expenses:						
Research and development	157.5	13 %	135.4	14 %	22.1	16 %
Selling, general and administrative	331.4	27 %	306.4	31 %	25.0	8 %
Total operating expenses	488.9	40 %	441.8	44 %	47.1	11 %
Operating income	242.5	20 %	152.0	15 %	90.5	60 %
Other income, net	109.8	9 %	25.4	3 %	84.4	**
Income before income taxes	352.3	29 %	177.4	18 %	174.9	99 %
Income tax expense	68.5	6 %	42.8	4 %	25.7	60 %
Net income	\$ 283.8	23 %	\$ 134.6	14 %	\$ 149.2	111 %
Basic net income per share	\$ 0.73	**	\$ 0.34	**	\$ 0.39	**
Diluted net income per share	\$ 0.70	**	\$ 0.34	**	\$ 0.36	**

⁽¹⁾ The sum of the individual percentages may not equal the total due to rounding.

** Not meaningful

Revenue

We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We expect that the revenue we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.

Cost of sales

Cost of sales includes direct labor and materials costs related to each product sold or produced, including assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations. Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based compensation, facility expense, supplies and purchased services. All of our manufacturing costs are included in cost of sales. In addition, amortization of certain licensing related intangibles are also included in cost of sales.

Research and development

Our research and development expenses primarily consist of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.

Selling, general and administrative


Our selling, general and administrative expenses primarily consist of employee compensation for our executive, financial, sales, marketing, information technology and administrative functions. Other significant expenses include commissions, marketing and advertising, IT software license costs, insurance, professional fees for our outside legal counsel and independent auditors, litigation expenses, patent application expenses and consulting expenses.

Other income, net

Other income, net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses resulting from the effects of foreign currency fluctuations, realized and unrealized gains and losses on marketable and non-marketable equity investments, including changes in fair value, and interest expense related to our senior convertible notes.

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

Revenue and Gross Profit Margin %



(In millions)	Three Months Ended September 30,				2025 - 2024	
	2025		2024		Change in Revenue	
	Revenue	% of Total	Revenue	% of Total	\$	%
United States	\$ 851.9	70%	\$ 701.9	71%	\$ 150.0	21%
International	357.4	30%	292.3	29%	65.1	22%
Total Revenue	\$ 1,209.3	100%	\$ 994.2	100%	\$ 215.1	22%

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

Revenue

The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base. We added approximately 500,000 - 600,000 net customers, excluding Stelo customers, to our worldwide customer base in 2024. The increase in revenue was offset by pricing headwinds due to rebate eligibility and channel mix.

Disposable sensor and other revenue comprised approximately 97% of total revenue and Reusable Hardware revenue comprised approximately 3% of total revenue for the three months ended September 30, 2025. Disposable sensor and other revenue comprised approximately 96% of total revenue and Reusable Hardware revenue comprised approximately 4% of total revenue for the three months ended September 30, 2024.

Cost of sales & Gross profit

Cost of sales and gross profit increased primarily due to an increase in sales volume driven by the addition of approximately 500,000 - 600,000 net customers, excluding Stelo customers, to our worldwide customer base in 2024.

The increase in gross profit margin percentage in the third quarter of 2025 compared to the third quarter of 2024 was primarily driven by higher manufacturing volumes which improved fixed cost absorption. This benefit was partially offset by inefficiencies associated with ensuring supply availability, build configurations that lowered production yield, and total replacement costs.

**Three Months Ended September 30, 2025 Compared to
Three Months Ended September 30, 2024**

<i>Research and development expense</i>	Research and development expense increased primarily due to \$16.4 million in higher compensation and related costs. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.
<i>Selling, general and administrative expense</i>	Selling, general and administrative expense increased primarily due to \$44.2 million in higher compensation and related costs, partially driven by increased headcount and \$10.2 million in incremental investments in advertising and marketing costs, offset by \$26.8 million in lower legal expense primarily related to a patent infringement lawsuit that was settled in December 2024.
<i>Other income, net</i>	Other income, net, increased primarily due to \$82.3 million in higher net gains on equity investments.
<i>Income tax expense</i>	The income tax expense recorded for the three months ended September 30, 2025 was primarily attributable to income tax expense from normal, recurring operations and the tax benefit related to the commencement of our Malaysia tax holiday. The income tax expense recorded for the three months ended September 30, 2024 was primarily attributable to income tax expense from normal, recurring operations and discrete impacts of certain foreign tax return filings. The decrease in our effective tax rate for the three months ended September 30, 2025 compared to the same period in 2024 is primarily attributable to a lower annual effective tax rate applied to normal, recurring operations and the tax benefit related to the commencement of our Malaysia tax holiday.

Results of Operations

Financial Overview

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024


(In millions, except per share amounts)	Nine Months Ended September 30,				2025 - 2024	
	2025	% of Revenue ⁽¹⁾	2024	% of Revenue ⁽¹⁾	\$ Change	% Change
Revenue	\$ 3,402.4	100 %	\$ 2,919.5	100 %	\$ 482.9	17 %
Cost of sales	1,393.2	41 %	1,137.1	39 %	256.1	23 %
Gross profit	2,009.2	59.1 %	1,782.4	61.1 %	226.8	13 %
Operating expenses:						
Research and development	450.9	13 %	412.9	14 %	38.0	9 %
Selling, general and administrative	969.5	28 %	958.4	33 %	11.1	1 %
Total operating expenses	1,420.4	42 %	1,371.3	47 %	49.1	4 %
Operating income	588.8	17 %	411.1	14 %	177.7	43 %
Other income, net	158.9	5 %	86.6	3 %	72.3	83 %
Income before income taxes	747.7	22 %	497.7	17 %	250.0	50 %
Income tax expense	178.7	5 %	73.2	3 %	105.5	**
Net income	\$ 569.0	17 %	\$ 424.5	15 %	\$ 144.5	34 %
Basic net income per share	\$ 1.45	**	\$ 1.08	**	\$ 0.37	34 %
Diluted net income per share	\$ 1.42	**	\$ 1.04	**	\$ 0.38	37 %

⁽¹⁾ The sum of the individual percentages may not equal the total due to rounding.

** Not meaningful

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024

Revenue and Gross Profit Margin %



(In millions)	Nine Months Ended September 30,				2025 - 2024	
	2025		2024		Change in Revenues	
	Revenue	% of Total	Revenue	% of Total	\$	%
United States	\$ 2,443.4	72%	\$ 2,087.0	71%	\$ 356.4	17%
International	959.0	28%	832.5	29%	126.5	15%
Total Revenue	\$ 3,402.4	100%	\$ 2,919.5	100%	\$ 482.9	17%

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024

Revenue

The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base. We added approximately 500,000 - 600,000 net customers, excluding Stelo customers, to our worldwide customer base in 2024. The increase in revenue was offset by pricing headwinds due to greater rebate eligibility and channel mix.

Disposable sensor and other revenue comprised approximately 97% of total revenue and Reusable Hardware revenue comprised approximately 3% of total revenue for the nine months ended September 30, 2025. Disposable sensor and other revenue comprised approximately 94% of total revenue and Reusable Hardware revenue comprised approximately 6% of total revenue for the nine months ended September 30, 2024.

Cost of sales & Gross profit

Cost of sales and gross profit increased primarily due to an increase in sales volume driven by the addition of approximately 500,000 - 600,000 net customers, excluding Stelo customers, to our worldwide customer base in 2024.

The decrease in gross profit margin percentage in 2025 compared to 2024 was primarily driven by inefficiencies associated with ensuring supply availability, build configurations that lowered production yield, and total replacement costs.

**Nine Months Ended September 30, 2025 Compared to
Nine Months Ended September 30, 2024**

<i>Research and development expense</i>	Research and development expense increased primarily due to \$37.1 million in higher compensation and related costs, offset by \$4.8 million in lower clinical trials, supplies, and other support costs. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.
<i>Selling, general and administrative expense</i>	Selling, general and administrative expense increased primarily due to \$77.7 million in higher compensation and related costs, partially driven by increased headcount, offset by \$72.4 million in lower legal expense primarily related to a patent infringement lawsuit that was settled in December 2024.
<i>Other income, net</i>	Other income, net, increased primarily due to \$79.5 million in higher net gains on equity investments and \$8.1 million in higher net foreign currency gains, offset by \$15.3 million in lower interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The decrease in interest income was primarily related to a change in market interest rates.
<i>Income tax expense</i>	The income tax expense recorded for the nine months ended September 30, 2025 was primarily attributable to income tax expense from normal, recurring operations at an estimated annual effective tax rate of 22.5%, increased by discrete shortfalls recognized for share-based compensation for employees, net of nondeductible executive compensation, offset by the tax benefit related to the commencement of our Malaysia tax holiday. The income tax expense recorded for the nine months ended September 30, 2024 was primarily attributable to income tax expense from normal, recurring operations at an estimated annual effective tax rate of 23.1%, partially offset by discrete excess tax benefits recognized for share-based compensation for employees, net of nondeductible executive compensation, the Verily milestone payment, and the impacts of certain foreign tax return filings. The increase in our effective tax rate for the nine months ended September 30, 2025 compared to the same period in 2024 is primarily attributable to impacts of shortfalls on share-based compensation, a non-recurring benefit related to the Verily milestone payment, offset by the tax benefit related to the commencement of our Malaysia tax holiday.

Liquidity and Capital Resources

Overview, Capital Resources, and Capital Requirements

Our principal sources of liquidity are our existing cash, cash equivalents and marketable securities, cash generated from operations, proceeds from our senior convertible notes issuances, and access to our Credit Facility. Our primary uses of cash have been for research and development programs, selling and marketing activities, capital expenditures, acquisitions of businesses, and debt service costs.

We expect that cash provided by our operations may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, working capital requirements and capital deployment decisions. We have historically invested our cash primarily in U.S. dollar-denominated, investment grade, highly liquid obligations of U.S. government agencies, commercial paper, corporate debt, and money market funds. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.

Our future capital requirements will depend on many factors, including but not limited to:

The evolution of the international expansion of our business and the revenue generated by sales of our approved products and any future products;	Our ability to efficiently scale our operations to meet demand for our current and any future products;	The success of our research and development efforts;
The expenses we incur in manufacturing, developing, selling and marketing our products;	The costs, timing and risks of delays of additional regulatory approvals;	The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
The quality levels of our products and services;	The emergence of competing or complementary technological developments;	The terms and timing of any collaborative, licensing and other arrangements that we may establish; and
The third-party reimbursement of our products for our customers;	The rate of progress and cost of our clinical trials and other development activities;	The acquisition of businesses, products and technologies and our ability to integrate and manage any acquired businesses, products and technologies.

We expect that existing cash and short-term investments and cash flows from our future operations will generally be sufficient to fund our ongoing core business. As current borrowing sources become due, we may be required to access the capital markets for additional funding. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. In the event that we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market in light of those earning levels.

A substantial portion of our operations are located in the United States, and the majority of our sales since inception have been made in U.S. dollars. As we continue to expand our manufacturing sites in Ireland and Malaysia, we will be subject to additional foreign exchange currency risk primarily related to our long-lived assets. See “Foreign Currency Exchange Risk” in Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, for more information.

Main Sources of Liquidity

Cash, cash equivalents and short-term marketable securities

Our cash, cash equivalents and short-term marketable securities totaled \$3.32 billion as of September 30, 2025. None of those funds were restricted and \$2.96 billion (approximately 89%) of those funds were located in the United States.

Cash flows from Operations

For the nine months ended September 30, 2025, we had positive cash flows of \$1.15 billion from operating activities. We anticipate that we will continue to generate positive cash flows from operations for the foreseeable future.

Senior Convertible Notes

We received net proceeds of \$1.19 billion in May 2020 from the 2025 Notes offering, and net proceeds of \$1.23 billion in May 2023 from the 2028 Notes offering. We used \$282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due in 2022. We used \$289.9 million of the net proceeds from the offering of the 2028 Notes to purchase capped call transactions and repurchase shares of our common stock in May 2023. We intend to use the remainder of the net proceeds for general corporate purposes and capital expenditures, including working capital needs. We may also use the net proceeds to expand our current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, we do not have any significant commitments with respect to any such acquisitions or investments at this time.

In connection with the 2028 Notes offering, we purchased the 2028 Capped Calls. See Note 4 “*Debt*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about our senior convertible notes and the 2028 Capped Calls.

Amended Credit Agreement

As of September 30, 2025, we had no outstanding borrowings, \$7.7 million in outstanding letters of credit, and a total available balance of \$192.3 million under the Amended Credit Agreement. We monitor counterparty risk associated with the institutional lenders that are providing the Credit Facility. We currently believe that the Credit Facility will be available to us should we choose to borrow under it. Revolving loans will be available for general corporate purposes, including working capital and capital expenditures. See Note 4 “*Debt*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Amended Credit Agreement.

Short-term Liquidity Requirements

As of September 30, 2025, our short-term liquidity requirements primarily consist of regular operating costs, interest payments related to our senior convertible notes, the principal payment related to the maturity of our 2025 Notes, capital expenditures for the development of our manufacturing facilities and office spaces, and short-term material cash requirements as described below. As of September 30, 2025, we had a working capital ratio of 1.56 and a quick ratio of 1.33, which indicates that our current assets are sufficient to cover our short-term liabilities. We expect to incur significant capital expenditures for the next year as we continue to invest in equipment and our manufacturing facilities.

As of September 30, 2025, we have \$1.21 billion of our outstanding 2025 Notes scheduled to mature on November 15, 2025, all of which will need to be repaid or refinanced, if not converted. We currently intend to repay the outstanding balance of the 2025 Notes in cash upon maturity. See Note 4 “*Debt—Senior Convertible Notes*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the 2025 Notes and our other senior convertible notes.

We believe that our cash, cash equivalents, and marketable securities balances, projected cash contributions from our commercial operations, and borrowings under our Credit Facility will be sufficient to meet our anticipated seasonal working capital needs, all capital expenditure requirements, material cash requirements as described herein, repay the remaining balance of the 2025 Notes, and meet other liquidity requirements associated with our operations for at least the next 12 months. We may continue to use cash to repurchase shares of our common stock, including pursuant to the 2025 Share Repurchase Program, or for other strategic initiatives that strengthen our foundation for long-term growth.

Long-term Liquidity Requirements

Our long-term liquidity requirements primarily consist of interest and principal payments related to our 2028 Notes, capital expenditures for the development of our manufacturing facilities and office spaces, and long-term material cash requirements as described below. As of September 30, 2025, we had a debt-to-assets ratio of 0.33, which indicates that our total assets are more than enough to cover our short-term and long-term debts. As demand grows for our products, we will continue to expand global operations to meet demand through investments in manufacturing and operations. We expect to meet our long-term liquidity requirements from our main sources of liquidity as described above to support our future operations, capital expenditures, acquisitions, and other liquidity requirements associated with our operations beyond the next 12 months.

As of September 30, 2025, we have outstanding senior convertible notes classified as long-term that will mature in May 2028. However, the outstanding principal of our senior convertible notes could be converted into cash and/or shares of our common stock prior to maturity once certain conditions are met. See Note 4 “*Debt—Senior Convertible Notes*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for information on conversion rights prior to maturity.

Material Cash Requirements

From time to time in the ordinary course of business, we enter into a variety of purchase arrangements including but not limited to, purchase arrangements related to capital expenditures, components used in manufacturing, and research and development activities. As of September 30, 2025, there were no material changes to our contractual obligations outside the ordinary course of business.

Our obligations under the 2025 Notes and 2028 Notes include both principal and interest payments. As of September 30, 2025, we have \$1.21 billion of our outstanding 2025 Notes scheduled to mature on November 15, 2025, all of which will need to be repaid or refinanced, if not converted. We currently intend to repay the outstanding balance of the 2025 Notes in cash upon maturity.

Prior to the maturity of the 2025 Notes and 2028 Notes in November 2025 and May 2028, respectively, they may be converted into cash and/or shares of our common stock if certain conditions are met. Any conversion prior to maturity may result in repayment of the principal amounts due under the Notes sooner than the scheduled repayment.

As market conditions warrant, we may, from time to time, repurchase our outstanding debt securities or shares of our common stock, including pursuant to the 2025 Share Repurchase Program, in the open market, in privately negotiated transactions, by exchange transaction or otherwise. Such repurchases, if any, will depend on prevailing market conditions, our liquidity and other factors and may be commenced or suspended at any time. The amounts involved and total consideration paid may be material. See Note 7 “*Stockholders’ Equity—Share Repurchase Program and Treasury Shares*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about our 2025 Share Repurchase Program.

See Note 4 “*Debt*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about the terms of the Amended Credit Agreement, our senior convertible notes, and the 2028 Capped Calls.

We are party to various leasing arrangements, primarily for office, manufacturing and warehouse space that expire at various times through December 2030, excluding any renewal options. We also have land leases in Penang, Malaysia that expire in 2082 and Athenry, Ireland that expire in 2023 related to our international manufacturing facilities. We anticipate incurring significant expenditures related to the build-out of our manufacturing facilities and investment in equipment. See Note 6 “*Leases and Other Commitments—Leases*” to the consolidated financial statements in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for more information about our leases. There were no material changes to our lease obligations during the nine months ended September 30, 2025.

Cash Flows

As of September 30, 2025, we had \$3.32 billion in cash, cash equivalents and short-term marketable securities, which is an increase of \$742.7 million compared to \$2.58 billion as of December 31, 2024.

The following table sets forth a summary of our cash flows and the primary changes in cash flows for the periods shown. See the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for the complete condensed consolidated statements of cash flows for these periods.

(In millions)	Nine Months Ended September 30,		
	2025	2024	\$ Change
Net cash provided by operating activities	\$ 1,146.7	\$ 688.1	\$ 458.6
Net cash provided by investing activities	229.4	96.2	133.2
Net cash used in financing activities	(164.2)	(733.2)	569.0
Effect of exchange rate changes on cash, cash equivalents and restricted cash	17.7	3.8	13.9
Increase in cash, cash equivalents and restricted cash	\$ 1,229.6	\$ 54.9	\$ 1,174.7

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024

Operating Cash Flows

\$144.5 million increase in net income
 \$162.1 million increase in net non-cash adjustments primarily due to adjustments to deferred income taxes, partially offset by net (gains) losses on equity investments
 \$152.0 million increase in net changes in operating assets and liabilities primarily due to the timing of payables and changes in accrued payroll due to lower variable compensation payments, partially offset by the timing of sales and customer collections in accounts receivables

Investing Cash Flows

\$172.8 million increase in net proceeds from marketable securities due to the management of our liquidity

Financing Cash Flows

\$562.8 million decrease in cash used to repurchase our common stock

Recent Accounting Guidance

See Note 1 “*Organization and Significant Accounting Policies*” to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements and the potential impact on our condensed consolidated financial statements, if any.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There were no material changes to our quantitative and qualitative disclosures about market risk during the nine months ended September 30, 2025. See Part II, Item 7A “*Quantitative and Qualitative Disclosures About Market Risk*” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, for a detailed discussion of our market risks.

ITEM 4 - CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Regulations under the Exchange Act require public companies to maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Disclosure controls and procedures include, without limitation, controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and timely communicated to management, including our President and Chief Operating Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Our management, with the participation of our President and Chief Operating Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on their evaluation as of September 30, 2025, our President and Chief Operating Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of such date.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitation on Effectiveness of Controls

It should be noted that any system of controls, including ours, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, we cannot guarantee that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II. OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.

Securities Class Actions

Between August 21 and October 9, 2024, three substantially similar putative class action complaints were filed against us and certain of our executive officers in the United States District Court for the Southern District of California. On December 13, 2024, the court appointed lead plaintiff court and consolidated the three actions (now captioned *In re Dexcom, Inc. Class Action Securities Litigation*, Lead Case No.: 24-cv-1485-RSH-VET). On January 27, 2025, lead plaintiff filed a consolidated complaint. The consolidated complaint alleges violations of the Exchange Act against us and certain of our current and former executive officers for allegedly making false and misleading statements between April 28, 2023 and July 25, 2024, with respect to our expected revenue for fiscal 2024 and ability to capitalize on our growth potential. On March 13, 2025, we filed a motion to dismiss the consolidated complaint. On May 14, 2025, the court granted the motion to dismiss with leave to amend. On May 28, 2025, lead plaintiff filed an amended consolidated complaint. On June 11, 2025, we filed a motion to dismiss the amended consolidated complaint. On October 7, 2025, defendants answered the amended consolidated complaint. On October 10, 2025, defendants filed a motion for judgment on the pleadings. The motion for judgment on the pleadings will be fully briefed on November 7, 2025.

On October 27, 2025, a putative class action complaint was filed against us and certain of our executive officers in the United States District Court for the Southern District of New York (captioned *Prime v. Dexcom, Inc., et al*, Case No.: 1:25-cv-08912). The complaint alleges violations of the Exchange Act against us and certain of our executive officers for allegedly making false and misleading statements between July 26, 2024 and September 17, 2025, with respect to the accuracy, reliability, and functionality of our G7 device, as well as our enhancements to and manufacturing of the device. Motions for lead plaintiff are due December 26, 2025.

Derivative Actions

Between September 13 and April 14, 2025, three putative stockholders filed derivative lawsuits against us and certain of our current and former executive officers and directors in the United States District Court for the Southern District of California. The derivative complaints allege factual allegations largely tracking allegations made in the *In re Dexcom, Inc. Securities Class Action Litigation* and seek, among other things, damages and restitution to be paid to the Company by the individual defendants, punitive damages, and attorney's fees and costs. These actions have been consolidated (captioned *In Re: Dexcom, Inc. Stockholder Derivative Litigation*, Lead Case No.: 24-cv-1645-RSH-VET), and were stayed until September 9, 2025, when the court granted in part and denied in part the motion to dismiss in the *In re Dexcom, Inc. Securities Class Action Litigation*. On October 24, 2025, the parties filed a joint motion to set a schedule for the filing of an amended consolidated complaint and briefing of any motion to dismiss filed in response thereto.

On September 25, 2025, an additional derivative lawsuit was filed against us and certain of our current and former executive officers and directors in the Court of Chancery of the State of Delaware. The allegations largely track those made in the *In re Dexcom, Inc. Securities Class Action Litigation* and seek, among other things, damages and restitution to be paid to the Company by the individual defendants, punitive damages, and attorney's fees and costs.

We intend to vigorously defend against such claims; however, we cannot be certain of the outcome of our ongoing proceedings and, if determined adversely to us, our business and financial condition may be adversely affected.

We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.

ITEM 1A - RISK FACTORS

The following risk factor supplements and, to the extent inconsistent, supersedes, the risk factors disclosed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 18, 2025. Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. Before making a decision to invest in, hold or sell our common stock, in addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, stockholders and potential stockholders should carefully consider the risks and uncertainties described in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which could materially and adversely affect our business, financial condition, results of operations and prospects. In that case, the value of our common stock could decline and stockholders may lose all or part of their investment.

Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business, financial condition, results of operations or prospects. Refer to our disclaimer regarding forward-looking statements at the beginning of Part I, Item 1 of this Quarterly Report on Form 10-Q.

If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.

Any product for which we obtain marketing approval, clearance or authorization (and the activities related to its production, distribution, and promotion, sale, and marketing) are subject to continual review and periodic inspections by the FDA and other regulatory bodies, which may include inspection of our manufacturing processes, complaint handling and adverse event reporting, post-approval clinical data and promotional activities for such product. The FDA's Medical Device Reporting, or MDR, regulations require that we report to the FDA any incident in which our product may have caused or contributed to a death or serious injury, or in which our product malfunctioned and, if the malfunction were to recur, it would likely cause or contribute to a death or serious injury.

If the FDA determines that there is a reasonable probability that a device intended for human use would cause serious, adverse health consequences or death, the agency may issue a cease distribution and notification order and a mandatory recall order. We may also decide to recall a product voluntarily if we find a material deficiency, including unacceptable risks to health, manufacturing defects, design errors, component failures, labeling defects, or other issues. Recalls of our products could divert the attention of our management and have an adverse effect on our reputation, financial condition, and operating results.

We and certain of our suppliers are also required to comply with the FDA's Quality System Regulation, or QSR, and other regulations which cover the methods and documentation of the design, testing, production, control, selection and oversight of suppliers or contractors, quality assurance, labeling, packaging, storage, complaint handling, shipping and servicing of our products. The FDA may enforce the QSR through announced (through prior notification) or unannounced inspections, such as the inspections described below.

Compliance with ongoing regulatory requirements can be complex, expensive and time-consuming. Failure by us or one of our suppliers or distributors to comply with statutes and regulations administered by the FDA, competent authorities and other regulatory bodies, or failure to take adequate response to any observations, including the warning letter described below, could result in, among other things, any of the following actions:

- warning letters or untitled letters that require corrective action;
- delays in approving, or refusal to approve, our CGM systems;
- fines and civil or criminal penalties;
- unanticipated expenditures;
- FDA refusal to issue certificates to international governments needed to export our products for sale in other countries;
- suspension or withdrawal of clearance or approval by the FDA or other regulatory bodies;
- product recall or seizure;
- administrative detention;
- interruption, partial suspension, or complete shutdown of production;

- interruption of the supply of components from our key component suppliers;
- operating restrictions;
- court consent decrees;
- FDA orders to repair, replace, or refund the cost of devices;
- injunctions; and
- criminal prosecution.

From time to time, the FDA issues Form 483 findings related to our operations and may issue warning letters or take other administrative or enforcement actions for noncompliance with FDA laws and regulations. In March 2025, we received an FDA warning letter following inspections of our facilities in San Diego, California, and Mesa, Arizona. In the warning letter, the FDA cited deficiencies in the response letters sent by us to the FDA following the Form 483, List of Investigational Observations that was delivered to us in connection with the inspection of our San Diego, California facility that occurred from October 2024 through November 2024, and the inspection of our Mesa, Arizona facility that occurred in June 2024. The warning letter describes observed non-conformities in manufacturing processes and our quality management system. We take the matters identified in the warning letter seriously and have already submitted responses to the Form 483 and to the FDA warning letter. While the warning letter does not restrict our ability to produce, market, manufacture or distribute products, require recall of any products, nor restrict our ability to seek FDA 510(k) clearance of new products, we may fail to satisfy these regulatory requirements to the FDA's satisfaction, and any failure to do so could result in the foregoing occurring.

While we intend to undertake certain corrective actions and provide regular updates to the FDA, we cannot give any assurances that the FDA will be satisfied with our response or as to the date we expect to resolve the matters included in the FDA warning letter. Until the issues cited in the warning letter are resolved to the FDA's satisfaction, additional legal or regulatory action may be taken without further notice, including as described above.

The potential effect of the warning letter and these other events can in some cases be difficult to quantify and could harm our reputation and cause our product sales and profitability to suffer. In addition, we believe events that could be classified as reportable events pursuant to MDR regulations are generally underreported by physicians and users, and any underlying problems could be of a larger magnitude than suggested by the number or types of MDRs filed by us. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements.

If we obtain regulatory approval to market and sell a product, the FDA or a foreign regulatory authority may still impose significant restrictions on the indicated uses or how the product may be marketed, or may contain requirements for costly post-marketing testing or surveillance to monitor the safety or effectiveness of the product. Later discovery of previously unknown problems with our products, including software bugs, unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as the QSR, MDR reporting, or other post-market requirements may result in restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls (through corrections or removals), fines, suspension of regulatory approvals, product seizures, injunctions, the imposition of civil or criminal penalties, or criminal prosecution. In addition, our distributors have rights to create marketing materials for their sales of our products, and may not adhere to contractual, legal or regulatory limitations that are imposed on their marketing efforts.

We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.

In April 2025, our Board of Directors authorized and approved the 2025 Share Repurchase Program, which provides for the repurchase of up to \$750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2026. Repurchases of our common stock under the 2025 Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, at our discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at our discretion. The 2025 Share Repurchase Program does not obligate us to repurchase any dollar amount or number of shares of our common stock, and the program may be extended, modified, suspended, or discontinued at any time.

The 2025 Share Repurchase Program could affect the price of our common stock and increase the volatility thereof. Price volatility may cause the average price at which we repurchase our common stock in a given period to exceed the stock's price at a given point in time. There can be no assurance that the timeframe for repurchases under our 2025 Share Repurchase Program or that any repurchases conducted thereunder will have a positive impact on our stock price or earnings per share. Important factors that could cause us to discontinue or decrease share repurchases under the 2025 Share Repurchase Program include, among others, unfavorable market conditions; the market price of our common stock; the nature of other investment or strategic opportunities presented to us from time to time; our ability to make appropriate, timely, and beneficial decisions as to when, how, and whether to repurchase shares under the 2025 Share Repurchase Program; and the availability of funds necessary to fulfill such repurchases. As of September 30, 2025, we have repurchased 2.4 million shares of our common stock for \$187.2 million under the 2025 Share Repurchase Program.

If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.

We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to pricing pressure from managed care organizations and other third-party payors.

In the United States and other countries, government and private sector access to health care products continues to be a subject of focus, and efforts to reduce health care costs are being made by third-party payors. Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7 and Dexcom One. We expect that these continuing cost reduction and containment measures could result in lower prices for these products and lower reimbursement rates, as well as could lead to patients being unable to obtain approval for coverage or payment from these third-party payors resulting in costs being shifted to patients for these products. Additionally, we may experience pricing pressure if our products are increasingly subject to competitive bidding processes, which include substantial costs and managerial time to prepare bids and proposals for contracts that may not be awarded to us or may be split among competitors. For example, in June 2025, the Centers for Medicare & Medicaid Services published a proposed rule that would subject continuous glucose monitors to the competitive bidding process, which could negatively impact our reimbursement and result in price decreases. To the extent these cost containment efforts are not offset by greater patient access to our products, our revenue may be reduced and our business may be harmed.

In addition to decreased pricing, we may be unable to reduce our expenses, including the cost of sourcing materials, logistics and the cost to manufacture our products. If the prices for our products decrease and/or if we are unable to offset the effects of general inflation on our operating costs through increases in the prices for our products, our business, results of operations, financial condition and cash flows will be adversely affected.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

The following table provides information regarding repurchases of our shares of common stock during the three months ended September 30, 2025:

Period	Total number of shares purchased ⁽²⁾	Average price paid per share ⁽¹⁾	Total number of shares purchased as part of publicly announced program ⁽²⁾	Maximum dollar value of shares that may yet be purchased under the program (in millions) ⁽²⁾
7/01/2025 - 7/31/2025	—	\$ —	—	\$ 750.0
8/01/2025 - 8/31/2025	1,998,100	\$ 78.57	1,998,100	\$ 593.0
9/01/2025 - 9/30/2025	406,399	\$ 74.45	406,399	\$ 562.8

⁽¹⁾ Average price paid per share includes broker commissions.

⁽²⁾ On May 1, 2025, we announced that our Board of Directors authorized and approved a share repurchase program of up to \$750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2026.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

None.

ITEM 5 - OTHER INFORMATION

Trading Plans

During the three months ended September 30, 2025, the following Section 16 officers and directors adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense of Rule 10b5-1(c):

Name	Title	Action	Action Date	Aggregate Number of Shares to be Sold	Expiration Date ⁽¹⁾
Richard A. Collins	Director	Adoption	8/7/2025	6,854	8/10/2026
Bridgette P. Heller	Director	Adoption	8/14/2025	4,048	8/18/2026

⁽¹⁾ Each trading arrangement permitted or permits transactions through and including the date listed in the table.

Each of the Rule 10b5-1 trading arrangements disclosed in the above table was made in accordance with our insider trading policy. Transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.

During the three months ended September 30, 2025, none of our Section 16 officers or directors adopted, modified, or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).

ITEM 6 - EXHIBITS

Exhibit Number	Exhibit Description	Incorporated by Reference				Provided Herewith
		Form	File No.	Date of First Filing	Exhibit Number	
31.1	Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).	—	—	—	—	X
31.2	Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a).	—	—	—	—	X
32.1**	Certification of Chief Principal Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).	—	—	—	—	X
32.2**	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).	—	—	—	—	X
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document					X
101.SCH	Inline XBRL Taxonomy Extension Schema Document					X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document					X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document					X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document					X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document					X
104	Cover Page Interactive Data File - the cover page from the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 is formatted in Inline XBRL					X

** This certification is not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that Dexcom specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DEXCOM, INC.
(Registrant)

Dated: October 30, 2025

By: /s/ JACOB S. LEACH

**Jacob S. Leach,
President and Chief Operating Officer
(Principal Executive Officer)**

Dated: October 30, 2025

By: /s/ JEREME M. SYLVAIN

**Jereme M. Sylvain,
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jacob S. Leach, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 30, 2025

By: /s/ JACOB S. LEACH
Jacob S. Leach
President and Chief Operating Officer
(Principal Executive Officer)

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jereme M. Sylvain, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 30, 2025

By: /s/ JEREME M. SYLVAIN

Jereme M. Sylvain
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350**

The undersigned, Jacob S. Leach, President and Chief Operating Officer (Principal Executive Officer) of DexCom, Inc. (the "Company"), pursuant to 18 U.S.C. §1350, hereby certifies that:

(i) the quarterly report on Form 10-Q for the quarter ended September 30, 2025 of the Company (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 30, 2025

/s/ JACOB S. LEACH

Jacob S. Leach

President and Chief Operating Officer
(Principal Executive Officer)

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350**

The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the "Company"), pursuant to 18 U.S.C. §1350, hereby certifies that:

(i) the quarterly report on Form 10-Q for the quarter ended September 30, 2025 of the Company (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 30, 2025

/s/ JEREME M. SYLVAIN

Jereme M. Sylvain
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)